REG - Surgical Innovations - Directorate changes and board succession planning

Surgical InnovationsAnnouncement

22/05/2023 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20230522:nRSV1108Aa&default-theme=true

RNS Number : 1108A  Surgical Innovations Group PLC  22 May 2023

Surgical Innovations Group Plc

(the "Company")

 

Directorate changes and board succession planning

 

Surgical Innovations Group Plc (AIM: SUN), the designer, manufacturer and
distributor of innovative technology for minimally invasive surgery, announces
the appointment of Jonathan Glenn as Senior Independent Non-executive Director
and Chairman-designate of the Company with immediate effect.

 

Jonathan is an experienced board director and chairman, with an excellent
track record in the medical device sector. He is currently Non-executive
Chairman of Tissue Regenix plc, and was formerly Group CEO of Consort Medical
Plc from 2007 to 2020, where he oversaw the £230m acquisition of a European
contract development and manufacturing organisation. Jonathan led the business
as CEO until its acquisition for £505m in 2020. Jonathan is a member of the
Institute of Chartered Accountants in England and Wales.

 

He joins the board in anticipation of the upcoming retirement of Professor
Mike McMahon, the founder of the Company, who retires from the board at the
Annual General Meeting of the Company expected to take place on 27 June
2023.

 

Following an orderly handover process, Jonathan will succeed Nigel Rogers as
Chairman upon announcement of the interim results expected in September 2023.
Nigel has indicated his intention to remain on the board until an additional
independent non-executive director has been appointed.

 

Chairman of the Company, Nigel Rogers, commented: "It has been my great
pleasure to lead the board since my appointment in 2015, and especially to
work alongside Prof. Mike McMahon. As part of our planned succession
arrangements, we are now delighted to have Jonathan joining us, and look
forward to working with him to complete the transition in board composition
for the next stage in the Company's evolution."

 

A separate announcement will be made in due course giving formal notice of the
Company's 2023 AGM.

 

The following information is disclosed pursuant to Rule 17 and Schedule Two
paragraph (g) of the AIM Rules for Companies:

 

Jonathan Martin Glenn (aged 54) is currently, or has during the past five
years, been a director of the following companies:

 

 Current directorships or partnerships      Previous directorships or partnerships
 ·    Tissue Regenix Group plc              ·    AESICA BC Limited

 ·    Tissue Regenix Holdings Limited       ·    AESICA Formulation Development Limited

 ·    TRX Cardiac Limited                   ·    AESICA Holdco Limited

 ·    TRX Orthopaedics Limited              ·    AESICA M1 Limited

 ·    TRX Vascular Limited                  ·    AESICA M2 Limited

 ·    TRX Wound Care Limited                ·    AESICA Queensborough Limited

 ·    Tissue Regenix Limited                ·    AESICA Trustee Company Limited

 ·    Tissue Regenix Holdings Inc           ·    Bespak Europe Limited

 ·    Tissue Regenix Wound Care Inc         ·    Bespak Finance Limited

 ·    TRX Orthopedics Inc                   ·    Bespak Holdings Limited

                                            ·    Binx Health Limited

                                            ·    Consort Medical Finance 2010 Limited

                                            ·    Consort Medical Finance Limited

                                            ·    Consort Medical Limited

                                            ·    Consort Medical plc

                                            ·    Integrated Aluminium Components Limited

                                            ·    Medical House (ASI) Limited

                                            ·    Medical House Products Limited

                                            ·    Pharmaron Manufacturing Services (UK) Ltd

                                            ·    The Medical House Group Limited

                                            ·    The Medical House Limited

 

 

Save as set out in this announcement there are no further details to be
disclosed in accordance with Rule 17 and Schedule Two Paragraph (g) of the AIM
Rule for Companies.

 

For further information please contact:

 

 Surgical Innovations Group plc                                                www sigroupplc com (http://www.sigroupplc.com/)
 David Marsh, CEO                                                              Tel: 0113 230 7597
 Charmaine Day, CFO

 Singer Capital Markets (Nominated Adviser & Broker)                                                     Tel: 020 7496 3000
 Aubrey Powell / Oliver Platts

 Walbrook PR (Financial PR & Investor Relations)      Tel: 020 7933 8780 or si@walbrookpr.com (mailto:si@walbrookpr.com)
 Paul McManus / Lianne Applegarth                                              Mob: 07980 541 893 / 07584 391 303

 

About Surgical Innovations Group plc

The Group specialises in the design, manufacture, sale and distribution of
innovative, high quality medical products, primarily for use in minimally
invasive surgery. Our product and business development is guided and supported
by a key group of nationally and internationally renowned surgeons across the
spectrum of minimally invasive surgical activity.

 

We design and manufacture and source our branded port access systems, surgical
instruments and retraction devices which are sold directly in the UK home
market through our subsidiary, Elemental Healthcare, and exported widely
through a global network of trusted distribution partners. Many of our
products in this field are based on a "resposable" concept, in which the
products are part reusable, part disposable, offering a high quality and
environmentally responsible solution at a cost that is competitive against
fully disposable alternatives.

 

Elemental also has exclusive UK distribution for a select group of specialist
products employed in laparoscopy, bariatric and metabolic surgery, hernia
repair and breast reconstruction.

 

In addition, we design and develop medical devices for carefully selected OEM
partners and have also collaborated with a major UK industrial partner to
provide precision engineering solutions to complex problems outside the
medical arena.

 

We aim for our brands to be recognised and respected by healthcare
professionals in all major geographical markets in which we operate and
provide by development, partnership or acquisition a broad portfolio of cost
effective, procedure specific surgical instruments and implantable devices
that offer reliable solutions to genuine clinical needs in the operating
theatre environment.

 

Further information

Further details of the Group's businesses and products are available on the
following websites:

www.sigroupplc.com (http://www.sigroupplc.com)

www.surginno.com (http://www.surginno.com)

www.elementalhealthcare.co.uk (http://www.elementalhealthcare.co.uk)

 

To receive regular updates by email, please contact si@walbrookpr.com
(mailto:si@walbrookpr.com)

 

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  BOAEASSFASEDEFA